September 28, 2018 5:46pm

As volatility stumbled and tumbled, share pricings closed with a negative Advance/Decline Line (A/DL) of our 45 covered companies

Volume has been increasing specific to the downside yet, a few upside moves also showed significant numbers

 

Pre-open indications:  4 HITs and 0 MISS

 

Out and about: review September’s closing metrics. In October and November, it will be a question of expectation versus share price weighting of LPS (loss-per-share) earnings, revenues, spending and “runways”

 

RMi is putting the facts into evidence for the metrics to “speak”!

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.


Henry’omics:

Friday also represents the final trading day of the third quarter. Over the past three months, the S&P has risen more than 7.2%, which would be its biggest quarterly advance since Q4/2013. The Dow is up about 9.3%; both the Dow and the S&P have risen in 11 of the past 12 quarters. The NASDAQ is up more than 7% over the quarter, and it is set for its ninth (9th) straight quarterly gain.

October is probably one of the more misread months … it isn’t that bad overall but, it is an extremely volatile month.

August and September historically have been weak; opening the door for the seasonally oriented Q4, kicking off with October.

Q4 LPS’ earnings will drive stock prices in either direction.

The first KEY for investing in some companies WILL be their “RUNWAYS”!

 

My pulpit of reason based on facts in evidence:

I also believe that there are few companies who have CRIMMINAL issues and should be called-out as MANY are just VEHICLES for day traders and NOT real institutional and retail investors <MY OPINION – Biostage (BSTG) – fighting a terminal death suit after an investor debilitating reverse split based on some internal issues re the lack of management, BOD oversight, financing and male/female harassment issues; Osiris (OSIR) - still under “surveillance and indictment  of NY’s Southern District; MiMedx (MDXG) – under review by NASDAQ,  lawyers focused on VA reimbursements, claw-back, BOD oversight and executive outings.

Keep an eye on the CRISPERS: CRISPR Therapeutics (CRSP -$2.09), Editas Medicine (EDIT -$0.59) and Intellia (NTLA -$0.16) – revenues, advancement of clinical initiatives to trials as well as responses to investors inquiries.

The second KEY will be – EXPECTATION as defined by the analysts covering their I-BANKING clients – will companies meet revenue, loss and per share projections as defined by operational  spending; debt as related to ATM usage.

… That’s why I stay INDEPENDENT to give investors the “facts as placed in evidence” which seems to be MY byline!

 

From the pre-open newsletter: “Today is the end of September’s sessions and Q3! The line in the sand is about to be drawn as to platform development, its quarterly costs and sector participant’s runway! Is there any light in the quarter’s shadows? The close will tell.”

 

Daily analytics and metrics:

  • The Dow closed up +18.38 points or +0.07% to 26,458.31
  • The S&P closed down -0.02 points or -0.00% to 2,913.98
  • The NASDAQ closed up +4.39 points or +0.05% to 8,046.35

 

The advance/decline line scenario of 45 covered companies:   

  • The open was positive with an A/DL of 28/15 and 2 flat;
  • The mid-day continued positive with an A/DL of 26/18 and 1 flat;
  • The close slipped negative with an A/DL of 20/25 and 3 flat;

 

Pre-open indications: 4 HITs and 0 MISS

  • Applied Genetic Technologies (AGTC) closed down -$0.05 – hit;
  • Athersys (ATHX) closed down -$0.08 – hit;
  • BioLife Solutions (BLFS) closed up +$0.27 – hit;
  • Fate Therapeutics (FATE) closed up +$0.62 – hit;

 

Of the 45 companies covered on Friday; 22 downside equities finished in a range of -0.13% (RGNX) to -5.53% (KOOL -$0.018) while 20 upside equity oscillated from +0.30% (SGMO) to +11.36% (ADRO) with 3  flat closes (OSIR, RENE.L and BCLI ).

 

Five (5) key metrics:  

… The greatest volume to the downside:  XON, BMRN, SGMO, ATHX and ALNY

… Upside volume was weighted to:  VSTM, MDXG, FATE, ADRO and BLUE

… Leadership ($) to the downside:  RARE (-$3.48), ALNY (-$2.57), CRSP (-$2.09), SLDB (-$1.88) and BMRN (-$1.00)

… Best moves ($) to the upside:  SAGE (+$3.14), BOLD (+$1.26), BLUE (+$1.05), ADRO (+$0.75) and FATE (+$0.62)

 

The iShares NASDAQ Biotechnology (IBB) closed:

  • Friday was up +0.06%
  • Thursday was up +1.04%
  • Wednesday was up +0.34 %
  • Tuesday was up +0.23 %
  • Monday was up +1.19%
  • Last Friday was down -0.62%

 

September sessions:

Friday’s closed NEGATIVE with 22 decliners, 20 advancers and 3 flat

Thursday’s closed POSITIVE with 19 decliners, 25 advancers and 1 flat

Wednesday’s closed NEGATIVE with 32 decliners, 12 advancers and 1 flat 

Tuesday’s closed POSITIVE with 20 decliners, 23 advancers and 3 flat 

Monday’s closed POSITIVE with 13 decliners, 28 advancers and 4 flat 

Friday’s closed NEGATIVE with 32 decliners, 11 advancers and 2 flat 

Thursday’s closed POSITIVE with 10 decliners, 34 advancers and 1 flat 

Wednesday’s closed POSITIVE with 18 decliners, 24 advancers and 3 flats 

Tuesday’s closed POSITIVE with 7 decliners, 36 advancers and 2 flats 

Monday’s closed NEGATIVE with 31 decliners, 12 advancers and 2 flats 

Friday’s closed POSITIVE with 19 decliners, 23 advancer and 3 flats 

Thursday’s closed NEGATIVE with 22 decliners, 20 advancer and 3 flats 

Wednesday’s closed POSITIVE with 20 decliners, 25 advancer and 0 flats 

Tuesday’s closed POSITIVE with 20 decliners, 23 advancer and 2 flats 

Monday’s closed NEGATIVE with 28 decliners, 17 advancer and 2 flats 

Friday’s closed POSITIVE with 15 decliners, 23 advancer and 7 flats 

Thursday’s closed NEGATIVE with 39 decliners, 1 advancer and 5 flats 

Wednesday’s closed NEGATIVE with 30 decliners, 12 advancers and 3 flats 

Tuesday’s (9/4) closed NEGATIVE with 22 decliners, 19 advancers and 4 flats  

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.